- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05486832
Safety and Performance of the Cardiovalve TR Replacement System (TARGET)
February 6, 2024 updated by: Cardiovalve Ltd.
Safety and Performance of the Cardiovalve TR Replacement System for Tricuspid Regurgitation
The objective of this study is to evaluate the safety and performance of Cardiovalve TR system
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study is a multi-center, prospective, single arm study designed to evaluate the safety and performance of the Cardiovalve Tricuspid Valve Replacement System
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nitza Shoham, PhD
- Phone Number: +972546882988
- Email: nitza@cardiovalve.com
Study Locations
-
-
-
Bad Oeynhausen, Germany, 32545
- Recruiting
- Universität Bochum
-
Contact:
- Rudolph Volker, MD
-
Berlin, Germany, 10117
- Recruiting
- Charité University
-
Contact:
- Sherif Mohammad, MD
-
Bonn, Germany, 53127
- Recruiting
- Uniklinik Bonn
-
Contact:
- Georg Nickenig, MD
-
Hamburg, Germany, 20251
- Recruiting
- Universitäres Herz
-
Contact:
- Niklas Schofer, MD
-
Köln, Germany, 50937
- Recruiting
- Herzzentrum Uniklinik
-
Contact:
- Adam Matti, MD
-
Lübeck, Germany, 20251
- Recruiting
- University Heart Center Lübeck
-
Contact:
- Christian. Frerker, MD
-
Regensburg, Germany, 93053
- Recruiting
- Universitätsklinikum - Regensburg
-
Contact:
- Michael Hilker, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Functional TR ≥3+
- Symptomatic, NYHA Class II-IVa
- Patient approved by the Subject Screening Committee
Exclusion Criteria:
- Cardiac anatomy deemed not suitable for the Cardiovalve TR system
- Hemodynamic instability
- Severe right ventricular failure
- Refractory heart failure requiring advanced intervention
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cardiovalve TR replacement Group
Cardiovalve TR valve replacement System
|
The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from device or procedure-related adverse events
Time Frame: 30 days
|
Freedom from device or procedure-related adverse events
|
30 days
|
Reduction in TR grade
Time Frame: 30 days
|
Reduction in TR in comparison to baseline
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six minute walk test
Time Frame: 30 days, 6 months, 12 months, annual for five years
|
Change in Six minute walk distance from Baseline
|
30 days, 6 months, 12 months, annual for five years
|
KCCQ
Time Frame: 30 days, 6 months, 12 months, annual for five years
|
Change in health status from Baseline
|
30 days, 6 months, 12 months, annual for five years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 9, 2022
Primary Completion (Estimated)
August 15, 2026
Study Completion (Estimated)
December 15, 2026
Study Registration Dates
First Submitted
August 2, 2022
First Submitted That Met QC Criteria
August 2, 2022
First Posted (Actual)
August 4, 2022
Study Record Updates
Last Update Posted (Actual)
February 7, 2024
Last Update Submitted That Met QC Criteria
February 6, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-21-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tricuspid Regurgitation
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health... and other collaboratorsActive, not recruitingTricuspid Regurgitation | Mild Tricuspid Regurgitation | Moderate Tricuspid RegurgitationUnited States, Canada, Germany
-
IRCCS Policlinico S. DonatoRecruitingTricuspid Regurgitation CongenitalItaly
-
Heart Center Leipzig - University HospitalRecruitingFunctional Tricuspid RegurgitationGermany
-
University of ZurichRecruitingSevere Tricuspid RegurgitationSwitzerland
-
P+F Products + Features GmbHCompletedSevere Tricuspid RegurgitationLithuania
-
Innoventric LTDNot yet recruitingTricuspid Regurgitation | Tricuspid Regurgitation Functional
-
Charite University, Berlin, GermanyRecruitingFunctional Tricuspid RegurgitationGermany, Israel
-
Michele De BonisCompleted
-
P+F Products + Features GmbHCompletedSevere Tricuspid RegurgitationSpain, Austria
-
Michele De BonisCompletedFunctional Tricuspid RegurgitationItaly
Clinical Trials on Cardiovalve TR valve replacement System
-
Cardiovalve Ltd.Meditrial Europe Ltd.Recruiting
-
Cardiovalve Ltd.Meditrial Europe Ltd.; Meditrial SrLRecruitingMitral Regurgitation | Mitral Valve DiseaseGermany, Italy, Greece
-
Boston Biomedical AssociatesCardiovascular Research Foundation, New York; Cardiovalve Ltd.Not yet recruitingTricuspid RegurgitationUnited States
-
Boston Biomedical AssociatesCardiovascular Research Foundation, New York; Cardiovalve Ltd.Active, not recruiting
-
Edwards LifesciencesActive, not recruitingCardiovascular Diseases | Heart Valve Diseases | Tricuspid Valve RegurgitationUnited States, Canada, France, Switzerland
-
Caisson Interventional LLCActive, not recruitingMitral Regurgitation | Valve Disease, Heart | Valve Heart Disease | Mitral Valve Disease | Mitral Valve Failure | Mitral DiseaseUnited States
-
Changhai HospitalXijing Hospital; West China Hospital; Second Affiliated Hospital, School of Medicine... and other collaboratorsRecruitingTricuspid Valve InsufficiencyChina
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With InsufficiencyAustria, Germany
-
Edwards LifesciencesActive, not recruitingMitral Valve Regurgitation (Degenerative or Functional)United States, Canada
-
Federal University of BahiaCompletedMitral Insufficiency | Mitral StenosisBrazil